NASDAQ:EXAS - Exact Sciences Stock Price Target and Predictions

Target and Analyst Ratings
Price Target History
Upgrades and Downgrades
About
FAQ

Consensus Rating: Buy
Consensus Price Target: $152.94
Forecasted Upside: 19.03 %
Number of Analysts: 18
Breakdown:
0 Sell Ratings
4 Hold Ratings
13 Buy Ratings
1 Strong Buy Ratings

^$128.49 As of 06/24/2021 01:00 AM ET

▼ -2.48 (-1.89%)

1 month | 3 months | 12 months

Get New Exact Sciences Analyst Ratings Delivered To Your Inbox

Sign-up to receive the latest news and ratings for EXAS and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for EXAS

^$152.94

▲ +19.03% Upside Potential

This price target is based on 18 analysts offering 12 month price targets for Exact Sciences in the last 3 months. The average price target is $152.94, with a high forecast of $180.00 and a low forecast of $120.00. The average price target represents a 19.03% upside from the last price of $128.49.

Current Consensus is Buy

The current consensus among 18 polled investment analysts is to buy stock in Exact Sciences. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details Read Past Recommendations Description Skip Past Price Target Consensus Chart

0 strong buy ratings
14 buy ratings
1 hold ratings
0 sell ratings

Ratings as of

1/1/2020

0 strong buy ratings
14 buy ratings
1 hold ratings
0 sell ratings

Ratings as of

3/31/2020

0 strong buy ratings
15 buy ratings
1 hold ratings
0 sell ratings

Ratings as of

6/29/2020

0 strong buy ratings
13 buy ratings
1 hold ratings
0 sell ratings

Ratings as of

9/27/2020

0 strong buy ratings
11 buy ratings
3 hold ratings
0 sell ratings

Ratings as of

12/26/2020

0 strong buy ratings
12 buy ratings
3 hold ratings
0 sell ratings

Ratings as of

3/26/2021

0 strong buy ratings
12 buy ratings
4 hold ratings
0 sell ratings

Ratings as of

5/25/2021

1 strong buy ratings
13 buy ratings
4 hold ratings
0 sell ratings

Ratings as of

6/24/2021

Latest Recommendations

Show Most Recent Rating from Each Ratings Firm Show All Ratings

Date	Brokerage	Action	Rating	Price Target	Impact on Share Price
6/21/2021	Wells Fargo & Company	Boost Price Target	Equal Weight	$115.00 ➝ $120.00	Low
6/15/2021	Raymond James	Initiated Coverage	Strong-Buy	$160.00	Medium
6/3/2021	The Goldman Sachs Group	Initiated Coverage	Buy	$160.00	Low
5/25/2021	Wells Fargo & Company	Initiated Coverage	Equal Weight	$115.00	Low
5/12/2021	Truist	Lower Price Target		$226.00 ➝ $168.00	Medium
5/12/2021	Truist Securities	Lower Price Target	Buy	$226.00 ➝ $168.00	Medium
5/5/2021	Craig Hallum	Lower Price Target	Buy	$161.00 ➝ $144.00	High
5/5/2021	BTIG Research	Lower Price Target	Buy	$175.00 ➝ $155.00	High
5/5/2021	SVB Leerink	Lower Price Target	Outperform	$180.00 ➝ $170.00	High
2/18/2021	Robert W. Baird	Lower Price Target	Outperform	$169.00 ➝ $163.00	Low
2/17/2021	Stifel Nicolaus	Boost Price Target	Buy	$150.00 ➝ $165.00	Low
2/17/2021	SVB Leerink	Boost Price Target	Market Perform ➝ Outperform	$170.00 ➝ $180.00	Low
2/17/2021	Cowen	Boost Price Target	Outperform	$154.00 ➝ $180.00	Low
1/27/2021	Truist	Initiated Coverage	Buy	$226.00 ➝ $226.00	Medium
1/21/2021	SVB Leerink	Boost Price Target	Outperform	$160.00 ➝ $170.00	Medium
1/12/2021	Canaccord Genuity	Boost Price Target	Buy	$160.00 ➝ $165.00	Low
10/29/2020	UBS Group	Downgrade	Buy ➝ Neutral	$125.00 ➝ $140.00	High
10/28/2020	Canaccord Genuity	Boost Price Target	Buy	$120.00 ➝ $145.00	Low
10/28/2020	Oppenheimer	Boost Price Target		$115.00 ➝ $150.00	Low
10/28/2020	BTIG Research	Boost Price Target		$140.00 ➝ $155.00	Low
10/28/2020	Smith Barney Citigroup	Downgrade	Buy ➝ Neutral	$120.00 ➝ $140.00	Low
10/28/2020	Robert W. Baird	Boost Price Target	Positive ➝ Outperform	$135.00 ➝ $150.00	Low
10/28/2020	SVB Leerink	Boost Price Target	Outperform	$115.00 ➝ $160.00	Low
10/28/2020	Benchmark	Boost Price Target	Buy	$110.00 ➝ $145.00	Low
10/28/2020	Citigroup Inc. 3% Minimum Coupon Principal Protected Based Upon Russell	Downgrade	Buy ➝ Neutral	$120.00 ➝ $140.00	Medium
9/25/2020	Canaccord Genuity	Boost Price Target	Buy	$115.00 ➝ $120.00	Low
7/31/2020	SVB Leerink	Boost Price Target	Outperform	$90.00 ➝ $115.00	High
7/31/2020	Benchmark	Boost Price Target	Buy	$90.00 ➝ $110.00	Low
7/31/2020	Citigroup	Boost Price Target	Buy	$110.00 ➝ $120.00	Low
7/8/2020	Oppenheimer	Reiterated Rating	Buy		High
6/25/2020	Citigroup	Boost Price Target	Buy	$100.00 ➝ $110.00	Medium
5/7/2020	Robert W. Baird	Boost Price Target	Outperform	$90.00 ➝ $92.00	Low
5/7/2020	Bank of America	Boost Price Target	Buy	$88.00 ➝ $94.00	Low
5/7/2020	Craig Hallum	Lower Price Target	In-Line ➝ Buy	$99.00 ➝ $92.00	Low
5/7/2020	Canaccord Genuity	Lower Price Target	Buy	$120.00 ➝ $110.00	High
5/7/2020	SVB Leerink	Lower Price Target	Outperform	$100.00 ➝ $90.00	High
4/28/2020	UBS Group	Lower Price Target	Buy	$135.00 ➝ $115.00	High
4/22/2020	Citigroup	Lower Price Target	Buy	$120.00 ➝ $100.00	Medium
4/22/2020	Robert W. Baird	Lower Price Target	Outperform	$100.00 ➝ $90.00	High
4/21/2020	Oppenheimer	Reiterated Rating	Buy	$115.00	Low
4/17/2020	Craig Hallum	Lower Price Target	Buy	$127.00 ➝ $99.00	High
4/2/2020	Stifel Nicolaus	Lower Price Target	Buy	$110.00 ➝ $90.00	Low
4/2/2020	Evercore ISI	Initiated Coverage	Outperform	$70.00	High
2/14/2020	Stifel Nicolaus	Reiterated Rating	Buy	$110.00	N/A
2/12/2020	Robert W. Baird	Reiterated Rating	Buy		Low
2/12/2020	Canaccord Genuity	Reiterated Rating	Buy	$120.00	High
2/6/2020	Canaccord Genuity	Reiterated Rating	Buy	$120.00	Low
1/10/2020	BTIG Research	Initiated Coverage	Buy	$127.00	High
1/6/2020	Citigroup	Initiated Coverage	Buy	$120.00	Low
12/13/2019	Dougherty & Co	Initiated Coverage	Buy	$120.00	Low
11/14/2019	Stifel Nicolaus	Initiated Coverage	Buy	$110.00	High
10/31/2019	Bank of America	Reiterated Rating	Buy	$135.00	Medium
10/30/2019	SVB Leerink	Lower Price Target	Outperform	$133.00 ➝ $105.00	Medium
10/30/2019	Canaccord Genuity	Lower Price Target	Buy	$135.00 ➝ $120.00	High
10/30/2019	Jefferies Financial Group	Lower Price Target	Buy	$138.00 ➝ $120.00	High
10/17/2019	Bank of America	Boost Price Target	Buy	$130.00 ➝ $135.00	Low
9/26/2019	Oppenheimer	Initiated Coverage	Outperform	$130.00	Medium
9/24/2019	SVB Leerink	Reiterated Rating	Buy		High
9/23/2019	Benchmark	Upgrade	Hold ➝ Buy	$130.00	High
9/10/2019	William Blair	Reiterated Rating	Buy		Low
9/10/2019	Canaccord Genuity	Reiterated Rating	Buy	$135.00	Low
8/1/2019	UBS Group	Boost Price Target	Buy	$120.00 ➝ $143.00	Low
7/30/2019	Craig Hallum	Boost Price Target	Buy	$115.00 ➝ $127.00	Medium
7/29/2019	Cowen	Boost Price Target	Outperform	$125.00 ➝ $135.00	Low
7/17/2019	Canaccord Genuity	Reiterated Rating	Buy	$118.00 ➝ $125.00	Low
5/1/2019	Jefferies Financial Group	Boost Price Target	Buy	$100.00 ➝ $115.00	Low
5/1/2019	UBS Group	Boost Price Target	Buy ➝ Buy	$115.00 ➝ $120.00	Low
5/1/2019	Craig Hallum	Reiterated Rating	Buy	$95.00 ➝ $115.00	Low
5/1/2019	Canaccord Genuity	Boost Price Target	Buy ➝ Buy	$100.00 ➝ $110.00	Medium
5/1/2019	BTIG Research	Boost Price Target	Buy	$130.00	Low
4/16/2019	UBS Group	Boost Price Target	Buy ➝ Buy	$109.00 ➝ $115.00	Low
2/26/2019	The Goldman Sachs Group	Upgrade	Neutral ➝ Buy	$85.00 ➝ $120.00	Medium
2/22/2019	UBS Group	Set Price Target	Buy	$109.00	Low
2/22/2019	Craig Hallum	Set Price Target	In-Line ➝ Buy	$77.00 ➝ $95.00	High
2/22/2019	BTIG Research	Boost Price Target	Buy ➝ Positive	$110.00	High
2/21/2019	Robert W. Baird	Boost Price Target	Outperform	$90.00 ➝ $102.00	High
1/28/2019	UBS Group	Boost Price Target	Buy	$100.00 ➝ $109.00	Medium
1/14/2019	Canaccord Genuity	Boost Price Target	Buy	$87.00 ➝ $95.00	High
1/7/2019	William Blair	Reiterated Rating	Outperform		High
11/29/2018	UBS Group	Set Price Target	Buy	$100.00	Low
10/31/2018	Jefferies Financial Group	Boost Price Target	Buy ➝ Buy	$74.00 ➝ $84.00	Low
10/30/2018	UBS Group	Set Price Target	Buy	$100.00	High
10/9/2018	UBS Group	Initiated Coverage	Buy ➝ Buy	$100.00	Low
9/12/2018	Canaccord Genuity	Boost Price Target	Buy ➝ Buy	$72.00 ➝ $87.00	Low
9/11/2018	Robert W. Baird	Boost Price Target	Outperform ➝ Outperform	$74.00 ➝ $85.00	Low
9/6/2018	Bank of America	Boost Price Target	Buy ➝ Buy	$68.00 ➝ $92.00	Medium
9/5/2018	Cowen	Boost Price Target	Outperform	$65.00 ➝ $100.00	High
9/5/2018	Benchmark	Reiterated Rating	Hold ➝ Hold		High
8/30/2018	The Goldman Sachs Group	Boost Price Target	Neutral	$75.00	Low
8/23/2018	Craig Hallum	Boost Price Target	Buy	$54.00 ➝ $74.00	Medium
8/23/2018	Jefferies Financial Group	Reiterated Rating	Buy	$74.00	High
8/23/2018	SVB Leerink	Reiterated Rating	Outperform	$90.00	High
8/23/2018	Robert W. Baird	Boost Price Target	Outperform ➝ Outperform	$65.00 ➝ $74.00	High
8/22/2018	BTIG Research	Boost Price Target	Buy	$95.00	High
8/13/2018	Canaccord Genuity	Reiterated Rating	Buy	$62.00 ➝ $65.00	Low
8/3/2018	Canaccord Genuity	Reiterated Rating	Buy	$62.00	Medium
8/2/2018	Jefferies Financial Group	Lower Price Target	Buy ➝ Buy	$60.00 ➝ $57.00	High
8/2/2018	Bank of America	Lower Price Target	Buy ➝ Buy	$75.00 ➝ $68.00	High
8/2/2018	Craig Hallum	Lower Price Target	Buy	$60.00 ➝ $54.00	High
7/23/2018	Bank of America	Boost Price Target	Buy ➝ Buy	$67.00 ➝ $75.00	Medium
7/18/2018	SVB Leerink	Reiterated Rating	Outperform ➝ Outperform	$67.00 ➝ $76.00	Low
7/9/2018	Robert W. Baird	Boost Price Target	Outperform ➝ Outperform	$66.00 ➝ $70.00	Low
6/18/2018	Cowen	Boost Price Target	Outperform	$65.00 ➝ $85.00	Low
6/15/2018	Canaccord Genuity	Boost Price Target	Buy	$70.00 ➝ $75.00	Medium
6/6/2018	Canaccord Genuity	Boost Price Target	Buy ➝ Buy	$68.00 ➝ $70.00	Low
6/5/2018	Robert W. Baird	Boost Price Target	Outperform ➝ Outperform	$58.00 ➝ $66.00	Medium
6/5/2018	BTIG Research	Reiterated Rating	Buy		Medium
5/31/2018	Canaccord Genuity	Reiterated Rating	Buy ➝ Buy	$60.00 ➝ $68.00	Medium
5/30/2018	BTIG Research	Boost Price Target	Positive ➝ Buy	$60.00 ➝ $70.00	High
4/29/2018	BTIG Research	Reiterated Rating	Buy	$60.00	High
4/27/2018	Canaccord Genuity	Boost Price Target	Buy ➝ Buy	$55.00 ➝ $60.00	High
4/3/2018	BTIG Research	Upgrade	Neutral ➝ Buy		Low
3/29/2018	William Blair	Reiterated Rating	Buy		N/A
3/28/2018	SVB Leerink	Set Price Target	Buy	$67.00	High
2/27/2018	Robert W. Baird	Upgrade	Neutral ➝ Outperform	$42.56 ➝ $56.00	Medium
2/23/2018	SVB Leerink	Set Price Target	Buy	$67.00	High
2/23/2018	Benchmark	Downgrade	Buy ➝ Hold		High
2/9/2018	SVB Leerink	Set Price Target	Buy	$67.00	Medium
1/29/2018	The Goldman Sachs Group	Initiated Coverage	Neutral ➝ Neutral	$17.77 ➝ $51.00	Low
1/17/2018	Benchmark	Set Price Target	Buy	$65.00	Medium
1/10/2018	William Blair	Reiterated Rating	Buy		High
1/8/2018	Bank of America	Set Price Target	Buy	$67.00	High
1/2/2018	William Blair	Reiterated Rating	Buy		Low
11/29/2017	Bank of America	Boost Price Target	Buy	$58.00 ➝ $67.00	Low
11/13/2017	SVB Leerink	Reiterated Rating	Outperform	$63.00 ➝ $67.00	N/A
11/13/2017	Robert W. Baird	Downgrade	Outperform ➝ Neutral	$56.00	N/A
11/1/2017	BTIG Research	Downgrade	Buy ➝ Neutral		N/A
10/31/2017	Bank of America	Boost Price Target	Buy	$56.00 ➝ $58.00	N/A
10/31/2017	Canaccord Genuity	Upgrade	Buy	$60.00	N/A
10/31/2017	Robert W. Baird	Boost Price Target	Outperform	$49.00 ➝ $56.00	N/A
10/31/2017	Craig Hallum	Boost Price Target	Buy	$46.00 ➝ $61.00	N/A
10/31/2017	Benchmark	Reiterated Rating	Buy ➝ Buy	$50.00 ➝ $60.00	N/A
10/31/2017	SVB Leerink	Reiterated Rating	Outperform	$50.00 ➝ $63.00	N/A
10/31/2017	Jefferies Financial Group	Boost Price Target	Buy	$60.00	N/A
10/19/2017	Bank of America	Set Price Target	Buy	$40.00 ➝ $56.00	N/A
10/6/2017	Robert W. Baird	Reiterated Rating	Buy	$49.00	N/A
10/3/2017	Canaccord Genuity	Reiterated Rating	Buy ➝ Buy	$45.00 ➝ $60.00	High
9/21/2017	SVB Leerink	Reiterated Rating	Outperform ➝ Outperform	$45.00 ➝ $50.00	High
9/7/2017	Canaccord Genuity	Reiterated Rating	Buy	$45.00	Low
8/24/2017	SVB Leerink	Set Price Target	Buy	$45.00	Medium
7/26/2017	Canaccord Genuity	Reiterated Rating	Buy ➝ Buy	$42.00 ➝ $45.00	High
7/26/2017	Bank of America	Reiterated Rating	Buy		High
7/26/2017	Roth Capital	Boost Price Target	Buy	$40.00 ➝ $46.00	High
7/26/2017	Craig Hallum	Reiterated Rating	Buy	$41.00 ➝ $46.00	High
7/26/2017	Lake Street Capital	Boost Price Target	Hold ➝ Hold	$30.00 ➝ $41.00	Medium
7/20/2017	Canaccord Genuity	Reiterated Rating	Buy	$38.00 ➝ $42.00	Medium
7/17/2017	BTIG Research	Reiterated Rating	Buy	$35.00 ➝ $45.00	Low
7/7/2017	Benchmark	Set Price Target	Buy	$50.00	Low
7/7/2017	Craig Hallum	Boost Price Target		$35.00 ➝ $41.00	High
6/12/2017	Bank of America	Reiterated Rating	Buy	$34.00 ➝ $38.00	Low
6/9/2017	Canaccord Genuity	Lower Price Target	Buy	$40.00 ➝ $38.00	Low
6/7/2017	Stephens	Set Price Target	Hold	$28.00	Medium
6/1/2017	Roth Capital	Reiterated Rating	Buy	$33.00 ➝ $40.00	Low
6/1/2017	Robert W. Baird	Reiterated Rating	Outperform	$40.00	Low
6/1/2017	Jefferies Financial Group	Set Price Target	Buy	$35.00	Medium
5/31/2017	Canaccord Genuity	Boost Price Target	Buy ➝ Buy	$38.00 ➝ $40.00	High
5/31/2017	Cowen	Reiterated Rating	Outperform	$45.00	High
5/31/2017	Benchmark	Boost Price Target	Buy ➝ Buy	$34.00 ➝ $50.00	High
5/16/2017	Jefferies Financial Group	Reiterated Rating	Buy	$35.00	Low
5/15/2017	Cowen	Boost Price Target	Outperform	$40.00 ➝ $45.00	N/A
5/5/2017	Cowen	Boost Price Target	Outperform	$40.00 ➝ $45.00	Low
5/1/2017	The Goldman Sachs Group	Set Price Target	Neutral	$21.00 ➝ $33.00	Medium
4/28/2017	SVB Leerink	Set Price Target	Buy	$38.00	Medium
4/27/2017	Cowen	Boost Price Target	Outperform ➝ Outperform	$30.00 ➝ $40.00	Low
4/26/2017	Jefferies Financial Group	Reiterated Rating	Buy	$25.00	High
4/24/2017	Canaccord Genuity	Reiterated Rating	Buy	$27.00	Low
4/17/2017	SVB Leerink	Initiated Coverage	Outperform ➝ Outperform	$30.00	Low
4/4/2017	Cowen	Reiterated Rating	Outperform	$30.00	Low
3/29/2017	Bank of America	Reiterated Rating	Buy		High
3/27/2017	Craig Hallum	Set Price Target	Buy	$28.00	High
3/27/2017	Cowen	Initiated Coverage	Outperform	$30.00	High
2/22/2017	Canaccord Genuity	Reiterated Rating	Buy	$27.00 ➝ $24.00	N/A
2/22/2017	Roth Capital	Upgrade	Neutral ➝ Buy	$15.00 ➝ $26.00	N/A
2/21/2017	Benchmark	Upgrade	Hold ➝ Buy	$17.00 ➝ $27.00	N/A
1/31/2017	Craig Hallum	Set Price Target	Buy	$26.00	N/A
1/23/2017	Canaccord Genuity	Set Price Target	Buy	$24.00	N/A
1/9/2017	Canaccord Genuity	Set Price Target	Buy	$24.00	N/A
1/8/2017	BTIG Research	Reiterated Rating	Buy	$22.00	N/A
12/20/2016	Robert W. Baird	Set Price Target	Buy	$22.00	N/A
12/13/2016	Canaccord Genuity	Set Price Target	Buy	$24.00	N/A
11/9/2016	Canaccord Genuity	Set Price Target	Buy	$24.00	N/A
11/1/2016	Lake Street Capital	Lower Price Target	Hold	$15.00 ➝ $8.00	N/A
10/28/2016	Canaccord Genuity	Reiterated Rating	Buy	$24.00	N/A
10/26/2016	Benchmark	Boost Price Target	Hold	$14.00 ➝ $17.00	N/A
10/4/2016	Jefferies Financial Group	Boost Price Target	Buy	$20.00 ➝ $23.00	N/A
9/4/2016	Craig Hallum	Set Price Target	Buy	$26.00	N/A
8/15/2016	The Goldman Sachs Group	Boost Price Target	Neutral	$16.00 ➝ $18.00	N/A
8/1/2016	Roth Capital	Reiterated Rating	Hold	$11.00 ➝ $15.00	N/A
7/31/2016	Robert W. Baird	Reiterated Rating	Outperform	$18.00	N/A
7/31/2016	BTIG Research	Reiterated Rating	Buy	$20.00	N/A
7/27/2016	Craig Hallum	Boost Price Target	Buy	$18.00 ➝ $26.00	N/A
7/27/2016	Jefferies Financial Group	Boost Price Target	Buy ➝ Buy	$13.00 ➝ $20.00	N/A
7/27/2016	Benchmark	Lower Price Target	Hold	$14.00 ➝ $9.00	N/A
7/27/2016	Mizuho	Boost Price Target	Neutral	$10.00 ➝ $15.00	N/A
7/26/2016	Canaccord Genuity	Reiterated Rating	Buy		N/A
7/15/2016	William Blair	Reiterated Rating	Outperform	$29.00	N/A

(Data available from 6/24/2016 forward)

Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX, a gene expression tests for breast, prostate, and colon cancers; Oncotype MAP, a tissue test delivering tumor profiling to aid therapy selection for patients with advanced, metastatic, refractory, or recurrent cancer; Oncotype DX AR-V7 Nucleus Detect Test, a liquid-based test for advanced stage prostate cancer; and Covid-19 testing services. The company's pipeline products focus on enhancing the Cologuard test's performance characteristics and developing blood and other fluid-based tests. It has license agreements with MAYO Foundation for Medical Education and Research; and Hologic, Inc. Exact Sciences Corporation was incorporated in 1995 and is headquartered in Madison, Wisconsin.

Today's Range

Now: $128.49

$128.00

$132.65

50 Day Range

MA: $116.46

$93.66

$139.27

52 Week Range

Now: $128.49

$70.75

$159.54

Volume

1,428,388 shs

Average Volume

1,652,635 shs

Market Capitalization

$22.04 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.29

Frequently Asked Questions

What sell-side analysts currently cover shares of Exact Sciences?

The following Wall Street analysts have issued reports on Exact Sciences in the last year: Benchmark Co., BTIG Research, Canaccord Genuity, Citigroup Inc., Citigroup Inc. 3% Minimum Coupon Principal Protected Based Upon Russell, Cowen Inc, Craig Hallum, Oppenheimer Holdings Inc., Raymond James, Robert W. Baird, Smith Barney Citigroup, Stifel Nicolaus, SVB Leerink LLC, The Goldman Sachs Group, Inc., TheStreet, Truist, Truist Securities, UBS Group AG, Wells Fargo & Company, and Zacks Investment Research.
View the latest analyst ratings for EXAS.

What is the current price target for Exact Sciences?

18 Wall Street analysts have set twelve-month price targets for Exact Sciences in the last year. Their average twelve-month price target is $152.94, suggesting a possible upside of 16.8%. Cowen Inc has the highest price target set, predicting EXAS will reach $180.00 in the next twelve months. Wells Fargo & Company has the lowest price target set, forecasting a price of $120.00 for Exact Sciences in the next year.
View the latest price targets for EXAS.

What is the current consensus analyst rating for Exact Sciences?

Exact Sciences currently has 4 hold ratings, 13 buy ratings and 1 strong buy rating from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe EXAS will outperform the market and that investors should add to their positions of Exact Sciences.
View the latest ratings for EXAS.

What other companies compete with Exact Sciences?

Other companies that are similar to Exact Sciences include Amgen, Gilead Sciences, Regeneron Pharmaceuticals, Biogen, Vertex Pharmaceuticals, Alexion Pharmaceuticals, Seagen, Alnylam Pharmaceuticals, Incyte, BioMarin Pharmaceutical, Novavax, Repligen, Neurocrine Biosciences, United Therapeutics and Exelixis.

How do I contact Exact Sciences' investor relations team?

Exact Sciences' physical mailing address is 5505 ENDEAVOR LANE, MADISON WI, 53719. The medical research company's listed phone number is 608-535-8815 and its investor relations email address is [email protected] The official website for Exact Sciences is www.exactsciences.com.